Artist rendering of AstraZeneca's planned antibody-drug conjugate facility in Singapore. (Credit: AstraZeneca)

As­traZeneca ear­marks $1.5B for end-to-end ADC fac­to­ry in Sin­ga­pore

As­traZeneca said on Mon­day morn­ing it is build­ing a new an­ti­body-drug con­ju­gate fa­cil­i­ty in Sin­ga­pore worth $1.5 bil­lion.

The UK phar­ma said this will be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.